-

New Cation Trap Column Workflow Improves Uptime for Anionic Contaminants Testing of Industrial Waters

The Thermo Scientific Dionex CR-CTC III application workflow offers cost-efficient trace-level analysis

SUNNYVALE, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc., the world leader in serving science, now offers nuclear power plants a new continuously regenerated cation trap column (CR-CTC) application workflow for robust and efficient trace anion contaminant testing of industrial waters.

The new Thermo Scientific Dionex CR-CTC III application workflow offers a solution to reduce the high cost and complexity of anion analysis in lithium borated water, and boiler and cooling water, in nuclear power plants. The workflow comprises the Thermo Scientific Dionex ICS-6000 capillary HPIC System or Thermo Scientific Dionex Integrion HPIC System and the Thermo Scientific Dionex IonPac AS28-Fast-4µm column, and allows for the determination of sub-µg/L anionic contaminants, utilizing a new single-step injection method of cation matrix elimination.

“This latest CR-CTC workflow aims to help reduce plant maintenance costs by minimizing plant and equipment corrosion through comprehensive trace anion contaminant analysis of industrial waters,” said Dino Alfano, vice president and general manager, ion chromatography and sample preparation, Thermo Fisher Scientific. “The new workflow provides optimum performance for nuclear power application requirements, such as removing lithium in borated waters by employing 100% carboxylate resin, and avoiding labile sulfonate that can end up in the cooling water as a corrosive anion.”

The new workflow offers a user-friendly experience, reducing the time required for training, and a single-step injection method of cation matrix elimination to increase productivity. The lower cost of ownership and maximized operational uptime help meet the ongoing increased energy demand.

Learn more about the new Thermo Scientific CR-CTC III application workflow.

About Thermo Fisher Scientific
Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue of approximately $40 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, increasing productivity in their laboratories, improving patient health through diagnostics or the development and manufacture of life-changing therapies, we are here to support them. Our global team delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services, Patheon and PPD. For more information, please visit www.thermofisher.com.

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

Thermo Fisher

NYSE:TMO
Details
Headquarters: Waltham, Massachusetts
CEO: Marc N. Casper
Employees: 100,000
Organization: PUB
Revenues: $40 Billion (2021)

Release Summary
The new Thermo Scientific Dionex CR-CTC III application workflow offers a solution to reduce the high cost and complexity of anion analysis.
Release Versions

Contacts

Media:
Laura Bright
Thermo Fisher Scientific
+1 562-335-8318
laura.bright@thermofisher.com

Janice Foley
BioStrata
+1 617-823-5555
jfoley@biostratamarketing.com

More News From Thermo Fisher

Thermo Fisher Scientific Launches New Color-Based (Chromogenic) Culture Media to Help Detect Candida Infections Faster*, Including Drug-Resistant Candida auris

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of Thermo Scientific™ Brilliance™ Candida 2 Agar and Spectra™ Candida Agar**, new color-based (chromogenic) culture media to help laboratories quickly detect and differentiate clinically important Candida species — including Candida auris, a growing global antimicrobial resistance (AMR) threat1. Invasive fungal infections are an increasing challenge for healthcare systems w...

Thermo Fisher Scientific Introduces New Laboratory Developed Test to Help Transplant Patients Receive the Right Dose of Critical Anti-Rejection Medication Sooner

WEST HILLS, Calif.--(BUSINESS WIRE)--Thermo Fisher Scientific, the world leader in serving science, today announced the launch of the TacroType™ Pharmacogenetic Test, a new laboratory developed test designed to help inform clinicians on dosing tacrolimus, a commonly prescribed immunosuppressive drug for transplant recipients to lower the risk of rejection. For transplant recipients, finding the right tacrolimus dose as early as possible can be life-changing. If the dose is too low, the body may...

Thermo Fisher Scientific Increases Quarterly Dividend

WALTHAM, Mass.--(BUSINESS WIRE)--Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced that its Board of Directors authorized a quarterly cash dividend of $0.47 per common share, payable on April 15, 2026, to shareholders of record as of March 13, 2026. This reflects a 10% increase over the previous dividend payment of $0.43. About Thermo Fisher Scientific Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue over $40...
Back to Newsroom